Buerger's disease, also known as thromboangiitis obliterans, is a rare condition that primarily affects young to middle-aged male smokers. The veins and arteries of the extremities constrict or block ...

DelveInsight’s, “Buerger’s Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger’s Disease pipeline landscape. It covers the ...

Buerger's disease, also known as thromboangiitis obliterans (TAO), is a non-atherosclerotic, inflammatory occlusive disease that predominantly affects small- and medium-sized arteries and veins of the ...

Buerger disease typically affects young or middle aged male cigarette smokers. The Food and Drug Administration (FDA) has granted Orphan Drug designation to AMB-301 for the treatment of Buerger ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Antidote Therapeutics, Inc., a biopharmaceutical company developing novel nicotine-blocking therapies to treat diseases caused or worsened by nicotine, announced ...

BASKING RIDGE, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to CLBS12, an investigational nongene-edited cell therapy for the ...

Ambulero Inc., a spinout from the University of Miami Miller School of Medicine, has received a positive response from a type B pre-IND meeting with the FDA on the development of AMB-301 as a ...

What ails Britain’s George VI? All public engagements would be canceled “over a period of some months.” The official bulletins had been medically vague. But at week’s end it was learned that the King ...